Literature DB >> 26956258

Association Between Time to Reperfusion and Outcome Is Primarily Driven by the Time From Imaging to Reperfusion.

Marc Ribo1, Carlos A Molina2, Erik Cobo2, Neus Cerdà2, Alejandro Tomasello2, Helena Quesada2, Maria Angeles De Miquel2, Mónica Millan2, Carlos Castaño2, Xabier Urra2, Luis Sanroman2, Antoni Dàvalos2, Tudor Jovin2.   

Abstract

BACKGROUND AND
PURPOSE: A progressive decline in the odds of favorable outcome as time to reperfusion increases is well known. However, the impact of specific workflow intervals is not clear.
METHODS: We studied the mechanical thrombectomy group (n=103) of the prospective, randomized REVASCAT (Randomized Trial of Revascularization With Solitaire FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset) trial. We defined 3 workflow metrics: time from symptom onset to reperfusion (OTR), time from symptom onset to computed tomography, and time from computed tomography (CT) to reperfusion. Clinical characteristics, core laboratory-evaluated Alberta Stroke Program Early CT Scores (ASPECTS) and 90-day outcome data were analyzed. The effect of time on favorable outcome (modified Rankin scale, 0-2) was described via adjusted odds ratios (ORs) for every 30-minute delay.
RESULTS: Median admission National Institutes of Health Stroke Scale was 17.0 (14.0-20.0), reperfusion rate was 66%, and rate of favorable outcome was 43.7%. Mean (SD) workflow times were as follows: OTR: 342 (107) minute, onset to CT: 204 (93) minute, and CT to reperfusion: 138 (56) minute. Longer OTR time was associated with a reduced likelihood of good outcome (OR for 30-minute delay, 0.74; 95% confidence interval [CI], 0.59-0.93). The onset to CT time did not show a significant association with clinical outcome (OR, 0.87; 95% CI, 0.67-1.12), whereas the CT to reperfusion interval showed a negative association with favorable outcome (OR, 0.72; 95% CI, 0.54-0.95). A similar subgroup analysis according to admission ASPECTS showed this relationship for OTR time in ASPECTS<8 patients (OR, 0.56; 95% CI, 0.35-0.9) but not in ASPECTS≥8 (OR, 0.99; 95% CI, 0.68-1.44).
CONCLUSIONS: Time to reperfusion is negatively associated with favorable outcome, being CT to reperfusion, as opposed to onset to CT, the main determinant of this association. In addition, OTR was strongly associated to outcome in patients with low ASPECTS scores but not in patients with high ASPECTS scores. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01692379.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  odds ratio; probability; reperfusion; stroke; thrombectomy

Mesh:

Year:  2016        PMID: 26956258     DOI: 10.1161/STROKEAHA.115.011721

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  27 in total

1.  Influence of a combined CT/C-arm system on periprocedural workflow and procedure times in mechanical thrombectomy.

Authors:  Johannes Pfaff; Silvia Schönenberger; Christian Herweh; Mirko Pham; Simon Nagel; Peter Arthur Ringleb; Sabine Heiland; Martin Bendszus; Markus Alfred Möhlenbruch
Journal:  Eur Radiol       Date:  2017-02-17       Impact factor: 5.315

2.  The Time-Reset Effect : Thrombectomy Trials Challenge the Existence of a Time Window.

Authors:  Jens Fiehler
Journal:  Clin Neuroradiol       Date:  2017-01-25       Impact factor: 3.649

3.  Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke.

Authors:  D Sacks; B Baxter; B C V Campbell; J S Carpenter; C Cognard; D Dippel; M Eesa; U Fischer; K Hausegger; J A Hirsch; M S Hussain; O Jansen; M V Jayaraman; A A Khalessi; B W Kluck; S Lavine; P M Meyers; S Ramee; D A Rüfenacht; C M Schirmer; D Vorwerk
Journal:  AJNR Am J Neuroradiol       Date:  2018-05-17       Impact factor: 3.825

4.  Two Paradigms for Endovascular Thrombectomy After Intravenous Thrombolysis for Acute Ischemic Stroke.

Authors:  Gaspard Gerschenfeld; Ioan-Paul Muresan; Raphael Blanc; Michael Obadia; Marie Abrivard; Michel Piotin; Sonia Alamowitch
Journal:  JAMA Neurol       Date:  2017-05-01       Impact factor: 18.302

5.  Relative cerebral blood volume is associated with collateral status and infarct growth in stroke patients in SWIFT PRIME.

Authors:  Juan F Arenillas; Elisa Cortijo; Pablo García-Bermejo; Elad I Levy; Reza Jahan; David Liebeskind; Mayank Goyal; Jeffrey L Saver; Gregory W Albers
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-14       Impact factor: 6.200

6.  Biomechanics and hemodynamics of stent-retrievers.

Authors:  Anna Luisa Kühn; Zeynep Vardar; Afif Kraitem; Robert M King; Vania Anagnostakou; Ajit S Puri; Matthew J Gounis
Journal:  J Cereb Blood Flow Metab       Date:  2020-05-19       Impact factor: 6.200

7.  Infarct Evolution in a Large Animal Model of Middle Cerebral Artery Occlusion.

Authors:  Mohammed Salman Shazeeb; Robert M King; Olivia W Brooks; Ajit S Puri; Nils Henninger; Johannes Boltze; Matthew J Gounis
Journal:  Transl Stroke Res       Date:  2019-09-03       Impact factor: 6.829

8.  Impact of onset-to-groin puncture time within three hours on functional outcomes in mechanical thrombectomy for acute large-vessel occlusion.

Authors:  Takahiro Ota; Yasuhiro Nishiyama; Satoshi Koizumi; Tomonari Saito; Masayuki Ueda; Nobuhito Saito
Journal:  Interv Neuroradiol       Date:  2017-12-13       Impact factor: 1.610

9.  Influence of procedure time on outcome and hemorrhagic transformation in stroke patients undergoing thrombectomy.

Authors:  Xianjun Huang; Qiankun Cai; Lulu Xiao; Mengmeng Gu; Yuanlu Liu; Zhiming Zhou; Wen Sun; Gelin Xu; Xinfeng Liu
Journal:  J Neurol       Date:  2019-07-03       Impact factor: 4.849

10.  Endovascular treatment outcomes using the Stroke Triage Education, Procedure Standardization, and Technology (STEPS-T) program.

Authors:  Ameer E Hassan; Christina Sanchez; Angela N Johnson
Journal:  Interv Neuroradiol       Date:  2017-11-09       Impact factor: 1.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.